LONDON – Diurnal plc has raised £30 million (US$44.7 million) in a listing on the Alternative Investment Market (AIM) in London and a convertible loan, enabling it to complete phase III development of two products based on its modified release version of hydrocortisone for treating congenital adrenal hyperplasia and adrenal insufficiency.